Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and September 2018

Showing 1 to 10 of 398
Title Reference number Published Last updated
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia Reference number:TA541 TA00541 Published:September 2018 20180901 Last updated:September 2018 20180919
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma Reference number:TA540 TA00540 Published:September 2018 20180901 Last updated:September 2018 20180903
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours Reference number:TA539 TA00539 Published:August 2018 20180801 Last updated:August 2018 20180829
Dinutuximab beta for treating neuroblastoma Reference number:TA538 TA00538 Published:August 2018 20180801 Last updated:August 2018 20180822
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine Reference number:TA535 TA00535 Published:August 2018 20180801 Last updated:August 2018 20180808
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer Reference number:TA536 TA00536 Published:August 2018 20180801 Last updated:August 2018 20180808
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs Reference number:TA537 TA00537 Published:August 2018 20180801 Last updated:August 2018 20180808
Dupilumab for treating moderate to severe atopic dermatitis Reference number:TA534 TA00534 Published:August 2018 20180801 Last updated:August 2018 20180801
Ocrelizumab for treating relapsing–remitting multiple sclerosis Reference number:TA533 TA00533 Published:July 2018 20180701 Last updated:July 2018 20180725
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Reference number:TA522 TA00522 Published:June 2018 20180601 Last updated:July 2018 20180724